Case Report

Synchronously diagnosed lymph nodal collision tumor of malignant melanoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: case report

Dina El Demellawy1, Catherine Ross2, Monalisa Sur2 and Salem Alowami*2

Address: 1Northern Ontario School of Medicine, Department Of Pathology and Laboratory Medicine, West Campus, Thunder Bay, Ontario, Canada and 2McMaster University, Department Of Pathology and Molecular Medicine, Hamilton, Ontario, Canada
Email: Dina El Demellawy - dina_eldemellawy@rogers.com; Catherine Ross - rossc@hhsc.ca; Monalisa Sur - surm@hhsc.ca; Salem Alowami* - alowami@hhsc.ca

* Corresponding author

Abstract

Synchronous composite tumors have been described but are uncommon. Moreover, simultaneous occurrence of synchronous tumors in the same tissue or organ is even less common. We report a case of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma and malignant melanoma (MM) occurring synchronously in the same lymph node. Several cases of an association between cutaneous malignancies and lymphoproliferative disorders have been reported. Some of which included CLL and MM, occurring in the same patient often CLL after MM. The risk of having CLL after MM has been reported to be increased. Various genetic and environmental etiologies have been postulated, but have as yet not been proven. To our knowledge this is the first time that synchronous occurrence of these two malignant processes in the same tissue is described. In this case it is important that the melanoma was recognized in the excised lymph node, as this finding had much more critical treatment and long term survival consequences.

Background

Synchronously diagnosed concomitant tumors are uncommon, and occurrence of collision tumors is rare. We report a case of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and malignant melanoma (MM) occurring synchronously in the same lymph node. CLL and MM occurring in the same patient, often CLL after MM with a standardized incidence ratio of 2.3 [1]. Nevertheless, the relative risk of having CLL after MM has been reported to be increased (standardized incidence ratio of 2.3) [1] and the converse (i.e. melanoma) after CLL also occurs with and estimated observed to expected ratio of 2.79 [2].

Various genetic and environmental etiologies have been postulated, but have as yet not been identified. To our knowledge this is the first time that synchronously diagnosed collision tumor formed of CLL/SLL and MM is described. In this case it is important that the melanoma was recognized in the excised lymph node, as this finding had much more critical treatment and long term survival consequences.

Case presentation

A 58 year old man presented with a right axillary mass, of 4 months duration. He was otherwise relatively well and asymptomatic. Past medical history was significant for two previous excisions of cutaneous lesions, which were
diagnosed as MM involving the left and right sides of the back, nine years and two years ago respectively. The patient has no history of receiving chemo or radiotherapy. A physical examination performed at this time revealed a right axillary mass with local tenderness measuring 10.0 × 8.0 cm. The patient had been experiencing night sweats, fevers and a twenty pound weight loss. The remainder of the physical examination was significant for splenomegaly, with the spleen tip palpated 7 cm. from the left lower costal margin. No other lymphadenopathy or organomegaly was detected.

**Hematologic investigations**

The peripheral blood showed a white blood cell count of 20.2 × 10⁹ (reference range: 5–11 × 10⁹). In addition, the CBC revealed hemoglobin value of 12.6 g/dl (reference range for men: 14.0–18.0 g/dl), and platelets was 203 × 10⁶/Liter (reference range: 150,000 to 450,000 platelets per microliter) of blood. The peripheral smear showed smudge cells.

As the patient presented with lymphadenopathy and showed leukocytosis in the peripheral blood, flow cytometry was performed on the patient’s peripheral blood. This showed a small population of monoclonal B cells with Kappa light chain restriction, indicating a lymphoproliferative disorder. The cells were CD5 and CD23 positive and CD38 and FMC7 negative. This phenotype is diagnostic of CLL in the presence of the morphological features in the peripheral blood smear.

Excision of the lymph node showed effacement of the normal nodal architecture by a lymphoproliferative disorder composed of small cells (fig. 1), which on immunohistochemistry [table 1] were CD20, CD5 (fig. 2), bcl-2 (fig. 3), CD23 (fig. 4) positive, CD10 and cyclin D1 negative compatible with small lymphocytic lymphoma. Only a single section showed a small metastatic focus of MM (fig. 5), measuring 1.5 mm in maximum diameter. This was of the epithelioid type that expressed MM markers, (fig. 6, 7) consistent with the previous diagnosis.

**Clinical outcome**

The patient had a re-excision of the growing axillary mass. He then had a new supraclavicular lymph node about one month later as well as persistent edema of the right arm. He received some radiation treatment at this time, after which he appeared stable for about four months. The patient then presented with shortness of breath and feeling unwell, and CT scan showed multiple nodules in the lung fields consistent with metastatic disease, at which time chemotherapy was started.

**Discussion**

Synchronously diagnosed collision tumors are considered a rare occurrence.

Cases presenting as multiple primary neoplasms may occur concurrently as collision tumors or may be separated temporally. It is important to realize that the constellation of neoplasms may be more than coincidental and may reflect underlying shared etiologic factors or may be related to altered immunity [3], particularly given the immunologic derangements that are known to occur with CLL. Of course, underlying genetic susceptibilities may also play important, although as yet not well delineated roles.

In the current case, we report a composite MM and CLL involving a single lymph node in a patient with MM diagnoses known previously. However, his past medical history indicates absence of chemo or radiotherapy; that may contribute to the present evolution of CLL. CLL and MM have been reported previously as a metachronously diagnosed tumors in the English literature with MM usually a subsequent cancer in patients with CLL [4].

---

**Table 1: The panel of immunohistochemical reagents used**

| Antibody | Clone | Manufacturer | Dilution |
|----------|-------|--------------|----------|
| CD 20    | L26   | Dako (Carpinteria, CA) | 1/1000 |
| Bcl 2    | 124   | Dako (Carpinteria, CA) | 1/25    |
| CD 5     | 4C7   | Novocastra (Vision Biosystem, Norwell, MA) | 1/50    |
| CD 23    | 1B12  | Novocastra (Vision Biosystem, Norwell, MA) | 1/50    |
| CD 10    | 56C6  | Novocastra (Vision Biosystem, Norwell, MA) | 1/25    |
| Cyclin D1| SP4   | MEDICORP/LAB VISION (Montreal, Quebec) | 1/75    |
| S 100    | S100  | Dako (Carpinteria, CA) | 1/4000  |
| Pan melanoma cocktail | HMB45, MART-1, Tyrosinase | BIOCARE MEDICAL (Concord, CA) | 1/500 |
| HMB 45   | HMB 45| Dako (Carpinteria, CA) | 1/200   |
developing after MM has also been reported. As far as we know only two synchronously diagnosed cases of CLL and MM have been reported previously in the English literature[5,3] [table 2], but none of these cases showed collision involvement of MM and CLL within the same site/organ.

Synchronously diagnosed collision tumors of non Hodgkin’s lymphomas (NHL) and MM have been reported involving the same lymph node [5-7]. Such reports include follicular, mantle and diffuse large cell lymphomas [5-7]. The current report adds to the list CLL and MM which is to the best of our knowledge is the first report of synchronously diagnosed CLL and MM involving the same node at the same time.

The association of malignant melanoma with other malignancies has been reported, including lymphoma, breast cancer, leukemia[8] and renal cell carcinoma [9]. In addition, there is a known risk of second malignant neoplasms in CLL patients, including malignancies of the lung, the brain and MM [2].

**Figure 1**
Lymph node involved with chronic lymphocytic leukemia showing architectural effacement, (HE 40×).

**Figure 2**
Restricted expression of CD5 within the lymphocytes in chronic lymphocytic leukemia in contrast to malignant melanoma cells, (CD5 200×).

**Figure 3**
Restricted expression of Bcl-2 within the lymphocytes in chronic lymphocytic leukemia in contrast to malignant melanoma cells, (Bcl-2 200×).

**Figure 4**
Restricted expression of CD23 within the lymphocytes in chronic lymphocytic leukemia in contrast to malignant melanoma cells, (CD23 200×).
Mature B cell neoplasms comprise ~4% of new cancers each year around the world [10] and they account for over 90% of lymphoid neoplasms worldwide [11]. About 6.7% of non-Hodgkin lymphomas are classified as SLL/CLL [11]. The majority of CLL patients are >50 years old with a median age of 65 years [12].

The median age at diagnosis of MM is 53 years as MM is now the commonest malignancy in Caucasians, between 25 and 29 years and in Caucasian men between 35–39 years [5]. The relative risk of subsequent MM for those with CLL has been estimated to be between 2.79 and 3.1 [13,14].

Patients who have MM have been ascribed a future risk of 1.9 for developing CLL [2].

There is no identifiable common cytogenetic abnormality or oncogene known between CLL and MM at this time. Risk factors for developing malignant melanoma are known to include ambient overexposure to sun light and perhaps chemical exposure in some studies. With respect to CLL, there are no proven studies to document sun light overexposure or chemical as risk factors. However, UVB present in sunlight has been suggested as a risk factor by inducing immunosuppressive effects through deficient antigen presentation and reduced T cell activity [15,16].

Composite tumors do raise the question of possible etiological links and are of academic interest from this point of view. More immediate questions include the impact of composite tumors on management and prognosis. Though CLL is eventually lethal, it usually takes a protracted and indolent course. The overall median survival of CLL is 7 years [10]. On the other hand, MM stage II and above presents a rather more significant survival threat. Most then would consider that the primary target is to manage the MM. Cytotoxic therapy, which is the mainstay of systemic therapy for lymphoma [17], has a limited efficacy in MM [5]. Although both MM and lymphoma are radiosensitive [18] this raises issues of secondary undesired consequences as radiation to areas of previous lymphadenectomy show a higher risk of subsequent lymphedema (~20%) [5].
We present a collision tumor of CLL and MM, a report to our knowledge has not been reported in the English literature. Through this case we reviewed the cases of synchronous CLL and MM and expanded on the incidence, demography, etiological correlation and management as well as prognostic implications. In this case the importance of diagnosing the small amount of malignant melanoma in the enlarged lymph node primarily occupied by CLL/SLL was of critical importance in this patient for decision making and treatment purposes, in addition to having a significant adverse impact on overall survival.

Acknowledgements
We thank the Board of Research Ethics in McMaster University for approving the current manuscript for publication.

References
1. McKenna DB, Stockton D, Brewster DH, Doherty VR: Evidence for an association between cutaneous malignant melanoma and lymphoid malignancy: a population-based retrospective cohort study in Scotland. Br J Cancer 2003, 88(1):74-78.
2. Riou JP, Ariyan S, Brandow KR, Fielding LP: The association between melanoma, lymphoma and other primary tumors. Arch Surg 1995, 130:1061-1065.
3. Schmid-Wendtner MH, Lebeau A, Sander CA, Volkenandt M, Emmerich B, Wendtner CM: Lymphadenopathy detected by ultrasound examination as first diagnostic hint of chronic lymphocytic leukemia in a patient with melanoma. JADAV 2002, 16:491-493.
4. Greene MH, Hoover RN, Fraumeni JF Jr: Subsequent cancer in patients with chronic lymphocytic leukemia – a possible immunologic mechanism. J natl Cancer Inst 1978, 61(2):337-340.
5. Cahill R, McGreai G, Neary P, Redmond HP: Synchronous high risk melanoma and lymphoid neoplasia. Melanoma Res 2001, 11(15):517-522.
6. Dickinson M, Wotherspoon A, Cunningham D: Sub-clinical dissemination of follicular lymphoma in normal sized lymph nodes may not be detected by radiological staging: a case of disseminated follicular lymphoma. 2006, 47(3):553-556.
7. St Peter SD, Roarke MC, Conley CR, Poczaj BA: Sentinel lymph node biopsy demonstrating concomitant melanoma and mantle cell lymphoma. Surgery 2002, 131:216-218.
8. Tihan T, Filippa DA: Coexistence of renal cell carcinoma and malignant lymphoma. Cancer 1996, 77:2325-2331.
9. Travis LB, Curtis RE, Hinkey BF, Fraumeni JF Jr: Second cancers in patients with chronic lymphocytic leukemia. J Natl Cancer Inst 1992, 84:1422-1427.
10. Harris NL: Mature B-cell neoplasms. In: tumors of hematopoietic and lymphoid tissues, World Health Organisation, 2001. Published by IARC Press, International Agency for Research on Cancer:121.
11. Anon: A predictive model for aggressive non Hodgkin's lymphoma. The international non Hodgkin's lymphoma prognostic factors project. N Engl J Med 1993, 329:987-994.
12. Muller-Hermelink HK, Montserrat E, Catovsky D, Harris NL: WHO classification of tumors: tumors of hematopoietic and lymphoid tissues IARC press, Lyon-France; 2001:127-129.
13. Adami J, Frisch M, Yuen J, Glimelius B, Melbye M: Evidence of an association between non Hodgkin's lymphoma and skin cancer. BMJ 1995, 310(6933):1491-1495.
14. Levi F, Randimbison L, Te VC, La Vecchia C: Non Hodgkin's lymphoma, chronic lymphocytic leukaemias and other skin cancers. Br J Cancer 1996, 74(11):1847-1850.
15. Streilein JW, Taylor JR, Vincek V, Kurimoto I, Shimizu T, Tie C, Golomb C: Immune surveillance and sun-light induced skin cancer. Immunal Today 1994, 15(4):174-179.
16. Saijo S, Buca DA, Ramirez KM, Cox PA, Kripke ML, Strickland PM: Deficient antigen presentation and Ts induction are separate effects of ultraviolet radiation. Cell Immunol 1995, 164(20):189-202.
17. Armitage JO: Chemotherapy for non Hodgkin's lymphoma. Curr Opin Oncol 1992, 4(5):189-202.
18. Shulman LN, Mauch PM: Current role of radiotherapy in Hodgkin's and non Hodgkin's lymphoma. Curr Opin Oncol 1995, 7(5):421-425.